Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
537 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (217)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01931163 | NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer(NECTAR) | completed | Phase 2 | 24 | Jenny C. Chang, MDOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT03411161 |
| S 81694 Plus Paclitaxel in Metastatic Breast Cancer |
| completed |
| Phase 1 / Phase 2 |
| 22 |
| Institut de Recherches Internationales ServierOTHER |
| 4 |
| May 25, 2021 |
| clinicaltrials |
| NCT02413320 | Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer(NeoSTOP) | completed | Phase 2 | 101 | Priyanka SharmaOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT03577743 | Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 54 | Assiut UniversityOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX)(GeparX) | completed | Phase 2 | 780 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT01271920 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | completed | Phase 1 / Phase 2 | 45 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT03106077 | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03140553 | TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer(neoCARH) | completed | Phase 2 | 140 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT02362958 | A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer | completed | Phase 2 | 159 | Sun Yat-sen UniversityOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT01855828 | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | completed | Phase 2 | 50 | Yale UniversityOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT00684983 | Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2020 | clinicaltrials |
| NCT00343109 | Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer | completed | Phase 2 | 38 | University of WashingtonOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT01355393 | Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01783756 | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | completed | Phase 1 / Phase 2 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01964924 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)(tnAcity) | completed | Phase 2 / Phase 3 | 191 | CelgeneINDUSTRY | 12 | Feb 21, 2019 | clinicaltrials |
| NCT02580448 | CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)(CLARITY-01) | completed | Phase 1 / Phase 2 | 175 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT00733408 | Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer | completed | Phase 2 | 59 | University of WashingtonOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT01091454 | Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 48 | Alliance for Clinical Trials in OncologyOTHER | 1 | May 8, 2018 | clinicaltrials |
| NCT00194779 | Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery | completed | Phase 2 | 50 | University of WashingtonOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01307891 | Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer | completed | Phase 2 | 64 | University of Alabama at BirminghamOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01688609 | Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Sep 11, 2017 | clinicaltrials |
| NCT00331552 | Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 / Phase 2 | 30 | University of WashingtonOTHER | 1 | Jul 26, 2017 | clinicaltrials |
| NCT01639248 | Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC | completed | Phase 2 | 41 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2017 | clinicaltrials |
| NCT00791037 | Vaccine Therapy in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 / Phase 2 | 23 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01306032 | Phase II ABT-888 With Cyclophosphamide | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 2 | Apr 26, 2017 | clinicaltrials |
| NCT01575522 | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2016 | clinicaltrials |
| NCT00813956 | A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer | completed | Phase 2 | 80 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01677455 | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer(Enchant) | completed | Phase 2 | 51 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Nov 5, 2015 | clinicaltrials |
| NCT00951054 | A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 61 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01969032 | Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer | completed | Phase 2 | 41 | Russian Academy of Medical SciencesOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00077376 | Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer | completed | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT01594177 | Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy(DAFNE) | completed | Phase 2 | 65 | GBG Forschungs GmbHOTHER | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00006228 | Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00098605 | Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jul 20, 2021source: clinicaltrials